| Another JPM in the books. We saw Big Pharmas talk up their pipelines, CEOs describe deal discipline, and one new company pitch the idea to sell better drugs, but cheaper. Plus, we finally got an answer to one of the most pertinent questions—where do they put all those missing hotel mattresses? But was it a slow week overall? Several execs weighed in on the conference’s lack of multi-billion, marquee M&A headlines compared to years prior, and what that could mean for the year ahead. Read on below for our top stories and roundups from San Francisco. | |
|
Featured Story | | | Tuesday, January 14, 2020 Big players jumped out to a fast start on-site at the J.P. Morgan Healthcare Conference Monday, with CEOs and top execs from Merck & Co., Gilead Sciences, Vertex Pharmaceuticals, Johnson & Johnson, Regeneron, Teva and more onstage (and in private rooms, of course). Here's your need to know. |
|
|---|
|
Top Stories Of The Week Monday, January 13, 2020 SAN FRANCISCO—We're always looking to ask the big questions at FierceBiotech, and, at this year's J.P. Morgan Healthcare Conference, we're asking: Where do all the orphaned mattresses go? Stick with us; it's a story of dealmaking madness at the biggest biopharma conference of the year. Wednesday, January 15, 2020 SAN FRANCISCO— At this year’s J.P. Morgan Healthcare Conference, we caught up with four women who had moved up the ranks in biopharma and are leading companies in their first CEO role: Synlogic's Aoife Brennan, Turning Point's Athena Countouriotis, Cygnal's Pearl Huang and Lyndra's Patricia Hurter. Thursday, January 16, 2020 For many attendees, this year’s J.P. Morgan Healthcare Conference didn’t seem to live up to its trademark frenetic energy. Last year, Bristol-Myers' $74 billion Celgene deal announcement—which happened just days before JPM—set the biopharma world abuzz, and Lilly kept the ball rolling with its $8 billion Loxo pact on Day 1 of the meeting. But this year? Crickets. Thursday, January 16, 2020 SAN FRANCISCO—It’s time to bring one of our favorite ASCO traditions to JPM. If you couldn’t be on the ground at this year’s conference, never fear—we’ve lovingly compiled all the zingers you missed in presentations and interviews we attended throughout the week. Monday, January 13, 2020 Last year, Bristol-Myers Squibb stole the show at the J.P. Morgan Healthcare Conference with its $74 billion deal agreement for Celgene. But one year later, with the deal just recently closed, company CEO Giovanni Caforio says he feels “even better about our opportunity” then he did when BMS unveiled it. Wednesday, January 15, 2020 SAN FRANCISCO—Novartis CEO Vas Narasimhan said this week the company has to become a “launch machine” to make current and upcoming rollouts pay off. Key to that effort will be its pharma chief, Marie-France Tschudin, who's revamping its launch strategies for a new era. Monday, January 13, 2020 SAN FRANCISCO—Roche has inked a 15-year partnership with Illumina in oncology, which will include collaborating on new companion diagnostic indications for the DNA sequencing giant’s pan-cancer assay. Tuesday, January 14, 2020 SAN FRANCISCO—Well, let’s start with the obvious, a pattern that has been set for a good few years now: There were no M&A deals on the so-called Merger Monday that typically kick-started the J.P. Morgan Healthcare Conference of old. Wednesday, January 15, 2020 SAN FRANCISCO—The second day of the annual J.P. Morgan Healthcare Conference again saw no major M&A deals but did see some of the bigger pharma companies present and talk a little more about their pipelines and R&D. Tuesday, January 14, 2020 A U.K.-based research team showed that in roundworm models of Parkinson's disease, probiotic Bacillus subtilis lessened the toxic buildup of alpha-synuclein in the brain—a major culprit in the disorder. That relieved tremors, movement difficulties and other motor symptoms, bolstering previous research showing a link between Parkinson's disease and the gut microbiome, the scientists believe. Friday, January 10, 2020 AbbVie and Allergan have waited expectantly to seal the deal on their $63 billion merger as international watchdogs took a close look at the combo. Now, they're almost home free. The EU says it's prepared to give a green light to the deal, provided the companies sell off Allergan's IL-23 med brazikumab. Monday, January 13, 2020 Eli Lilly has killed off its deal with immuno-oncology biotech NextCure after spending $25 million upfront on the pact just over a year ago. Monday, January 13, 2020 The recalls of generic Zantac tainted by a suspected carcinogen continue to roll in. Two more companies have announced recalls of 18 lots of ranitidine heartburn meds in 150 mg and 300 mg doses. | | [Webinar] InCrowd’s 2020 Healthcare Predictions Tuesday, February 11 | 1pm ET / 10am PT How will 2020 change US healthcare? InCrowd’s physicians weigh in on what the new year will bring. Join Diane Hayes, PhD, InCrowd Co-Founder and Board Member and Daniel S. Fitzgerald, InCrowd CEO and President, for InCrowd’s 2020 Healthcare Predictions Webinar. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: DocuSign A digital transformation is taking place in the life sciences industry, from research laboratories to manufacturing facilities. But there has always been a gap in these technologies. Download the whitepaper to learn how this challenge was addressed. Sponsored by: DocuSign This paper discusses some of the challenges that the GDPR will introduce, with a particular focus on its requirements for obtaining verifiable, unambiguous consent. Sponsored by: DocuSign Download this paper to learn how you can fully digitize all paper processes. By doing so, you will see shorter cycle times, reduced development costs, and greater customer satisfaction. Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Colorcon Learn more: Best practices for defending supply chain security and compliance by efficiently managing product authentication. Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. |
